Genomics & Sequencing Instruments
OEMs producing DNA sequencers, PCR systems, and genomics platforms.
Market snapshot
These figures describe Life Science Instruments (5.12.4), the segment that Genomics & Sequencing Instruments sits within — not Genomics & Sequencing Instruments on its own.
Life-science instruments overlap analytical-instrument and electromedical classifications (NAICS 334516 and related) and are not separately disclosed by the Census Bureau, so the segment is not separately sized here.
Business model & economics
Revenue model
Instrument placements pulling through recurring reagents/consumables
Key economics
- Recurring revenue
- High
- EBITDA margin
- Strong
- Capex intensity
- Moderate
very strong recurring reagent/consumable pull-through
razor-and-blade life-science economics
Characteristics
- Led by Illumina, Danaher, Thermo Fisher, Bio-Rad.
- Genomics, precision medicine, and cell/gene therapy drive demand.
- Powerful recurring reagent/consumable economics.
M&A deal context
Who’s acquiring
- Life-science instrument majors
- Serial-acquirer platforms
- PE- and VC-backed innovators
What’s driving deals
- Genomics and precision-medicine growth.
- Reagent/consumable razor-and-blade economics.
- Acquisition of platform and assay innovation.
Find Genomics & Sequencing Instruments acquisition targets
Search Acquisera’s index for companies classified under Genomics & Sequencing Instruments (5.12.4.2) and build a targeted deal pipeline.
Search companies